Literature DB >> 30214734

A cross-sectional survey of methods for controling hand-foot syndrome in patients receiving capecitabine treatment.

Shinya Suzuki1, Shuichi Nawata2, Yusuke Inada3, Daisuke Sato4, Junichi Kusano1, Daisuke Ichikura2, Kazuhiro Torigoe5, Kazumi Ishitsuka5, Fumiaki Sato6, Hiroyasu Sakai6, Tetsuro Yumoto6.   

Abstract

Medical personnel actively provide patients taking capecitabine with information on the items to prevent and treat hand-foot syndrome (HFS). However, they are typically unable to ascertain the extent of patient compliance with the recommended items. Thus, the aim of the present study was to ascertain the association between patient compliance with preventative measures for HFS and the development of HFS. Subjects included 90 patients who were treated with a drug regimen that included capecitabine. Patients were treated at one of four facilities between July 2015 and January 2017. The main parameters studied were the extent to which items to prevent and treat HFS were (or were not) followed, and the associaiton between this extent and the development of HFS symptoms. A manual prepared by a pharmaceutical company that manufactures capecitabine describes 15 routine items to follow in order to prevent and treat HFS. The two activities patients most often performed were 'applying a moisturizer' (74.1%) and 'keeping one's skin clean (e.g., washing one's hands and feet)' (64.7%). The two activities patients least often performed were 'using sunscreen on exposed areas' (14.1%) and 'using soft insoles' (11.8%). Patients who performed more items to prevent and treat HFS were significantly less likely to develop symptoms of HFS (P=0.022). Based on these findings, it is recommended that medical personnel provide instructions to the patients regarding the specific items necessary to prevent and treat HFS, and to follow-up with the patients regarding their compliance, with an emphasis on the items they are less likely to take and on the instructions to avoid external irritants. Following these guidelines should lead to qualitative improvement in HFS management.

Entities:  

Keywords:  capecitabine; hand-foot syndrome; hand-foot syndrome atlas; moisturizer; patient management

Year:  2018        PMID: 30214734      PMCID: PMC6125699          DOI: 10.3892/mco.2018.1689

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  10 in total

Review 1.  A case of bleomycin-induced acral erythema (AE) with eccrine squamous syringometaplasia (ESS) and summary of reports of AE with ESS in the literature.

Authors:  Hiromi Tsuboi; Kohzoh Yonemoto; Kensei Katsuoka
Journal:  J Dermatol       Date:  2005-11       Impact factor: 4.005

2.  [Neurotoxicity and dermatologic toxicity of cancer chemotherapy].

Authors:  Minoru Nakane
Journal:  Gan To Kagaku Ryoho       Date:  2006-01

Review 3.  Management of hand-foot syndrome induced by capecitabine.

Authors:  Sarah M Gressett; Brad L Stanford; Fred Hardwicke
Journal:  J Oncol Pharm Pract       Date:  2006-09       Impact factor: 1.809

4.  Risk Factors Exacerbating Hand-Foot Skin Reaction Induced by Capecitabine plus Oxaliplatin with or without Bevacizumab Therapy.

Authors:  Takashi Yokokawa; Kazuyoshi Kawakami; Yutaro Mae; Kazuo Sugita; Hiroshi Watanabe; Kenichi Suzuki; Mitsukuni Suenaga; Nobuyuki Mizunuma; Toshiharu Yamaguchi; Toshihiro Hama
Journal:  Ann Pharmacother       Date:  2015-07-09       Impact factor: 3.154

5.  Capecitabine as adjuvant treatment for stage III colon cancer.

Authors:  Chris Twelves; Alfred Wong; Marek P Nowacki; Markus Abt; Howard Burris; Alfredo Carrato; Jim Cassidy; Andrés Cervantes; Jan Fagerberg; Vassilis Georgoulias; Fares Husseini; Duncan Jodrell; Piotr Koralewski; Hendrik Kröning; Jean Maroun; Norbert Marschner; Joseph McKendrick; Marek Pawlicki; Riccardo Rosso; Johannes Schüller; Jean-François Seitz; Borut Stabuc; Jerzy Tujakowski; Guy Van Hazel; Jerzy Zaluski; Werner Scheithauer
Journal:  N Engl J Med       Date:  2005-06-30       Impact factor: 91.245

Review 6.  Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management.

Authors:  E Nagore; A Insa; O Sanmartín
Journal:  Am J Clin Dermatol       Date:  2000 Jul-Aug       Impact factor: 7.403

Review 7.  Management of hand-foot syndrome in patients treated with capecitabine (Xeloda).

Authors:  Yvonne Lassere; Paulo Hoff
Journal:  Eur J Oncol Nurs       Date:  2004       Impact factor: 2.398

8.  Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.

Authors:  W Scheithauer; J McKendrick; S Begbie; M Borner; W I Burns; H A Burris; J Cassidy; D Jodrell; P Koralewski; E L Levine; N Marschner; J Maroun; P Garcia-Alfonso; J Tujakowski; G Van Hazel; A Wong; J Zaluski; C Twelves
Journal:  Ann Oncol       Date:  2003-12       Impact factor: 32.976

Review 9.  Incidence and implications of chemotherapy related hand-foot syndrome.

Authors:  V Nikolaou; K Syrigos; M W Saif
Journal:  Expert Opin Drug Saf       Date:  2016-10-08       Impact factor: 4.250

10.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer.

Authors:  Toshiaki Watanabe; Michio Itabashi; Yasuhiro Shimada; Shinji Tanaka; Yoshinori Ito; Yoichi Ajioka; Tetsuya Hamaguchi; Ichinosuke Hyodo; Masahiro Igarashi; Hideyuki Ishida; Soichiro Ishihara; Megumi Ishiguro; Yukihide Kanemitsu; Norihiro Kokudo; Kei Muro; Atsushi Ochiai; Masahiko Oguchi; Yasuo Ohkura; Yutaka Saito; Yoshiharu Sakai; Hideki Ueno; Takayuki Yoshino; Narikazu Boku; Takahiro Fujimori; Nobuo Koinuma; Takayuki Morita; Genichi Nishimura; Yuh Sakata; Keiichi Takahashi; Osamu Tsuruta; Toshiharu Yamaguchi; Masahiro Yoshida; Naohiko Yamaguchi; Kenjiro Kotake; Kenichi Sugihara
Journal:  Int J Clin Oncol       Date:  2015-03-18       Impact factor: 3.402

  10 in total
  1 in total

1.  Effect of Chinese Herbal Compound LC09 on Patients With Capecitabine-Associated Hand-Foot Syndrome: A Randomized, Double-Blind, and Parallel-Controlled Trial.

Authors:  Ran Yu; Xuefeng Wu; Liqun Jia; Yanni Lou
Journal:  Integr Cancer Ther       Date:  2020 Jan-Dec       Impact factor: 3.279

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.